Part

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Retrieved on: 
Saturday, December 9, 2023

Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.

Key Points: 
  • Twenty patients in Part 1a were treated with either bezuclastinib or placebo plus best supportive care for all arms.
  • Patients were enrolled with the following sub-types: 18 patients with indolent systemic mastocytosis (ISM) and two patients with smoldering systemic mastocytosis (SSM).
  • In patients with completed questionnaires:
    By week 12, bezuclastinib patients showed a median best improvement of 37% on MC-QoL vs. 24% for placebo patients.
  • Data from Part 1 of the Phase 2 APEX clinical trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM) will be presented in a poster session at ASH on Monday, December 11, 2023 at ASH.

SLRN Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of Securities Fraud Class Action Lawsuit

Retrieved on: 
Friday, December 8, 2023

The action charges Acelyrin with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.

Key Points: 
  • The action charges Acelyrin with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company’s business, operations, and prospects.
  • As a result of Acelyrin’s materially misleading statements and omissions to the public, Acelyrin’s investors have suffered significant losses.
  • Kessler Topaz Meltzer & Check, LLP encourages Acelyrin investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ACELYRIN, Inc. (SLRN)

Retrieved on: 
Thursday, December 7, 2023

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Acelyrin conducted its initial public offering (“IPO”), selling 30 million shares of common stock at $18 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Acelyrin (SLRN) Discloses CRO Errors in Izokibep Program in Wake of Investor Class Action - Hagens Berman

Retrieved on: 
Thursday, December 7, 2023

Acelyrin, Inc. (NASDAQ: SLRN) Securities Fraud Class Action:

Key Points: 
  • Acelyrin, Inc. (NASDAQ: SLRN) Securities Fraud Class Action:
    “The litigation focuses on whether Acelyrin may have misrepresented or concealed data that did not support the hypothesized benefits of izokibep,” said Reed Kathrein, the Hagens Berman partner leading the investigation.
  • Recently, on Nov. 27, 2023, Acelyrin announced that it will be conducting a comprehensive review of the development program for izokibep after it discovered critical dosing errors committed by contract research organization (CRO) Fortrea.
  • The announcement comes on the heels of a securities class action lawsuit filed on Nov. 15.
  • The clinical trial “execution errors” Acelyrin disclosed two weeks after the securities suit was filed purportedly affected a psoriatic arthritis trial of izokibep.

ACELYRIN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

Retrieved on: 
Thursday, December 7, 2023

NEW YORK, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) and reminds investors of the January 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Acelyrin’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical Trial

Retrieved on: 
Tuesday, December 5, 2023

The Research Tringle Park–headquartered biotechnology company plans to share its initial findings on December 6 at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference in Phoenix, AZ.

Key Points: 
  • The Research Tringle Park–headquartered biotechnology company plans to share its initial findings on December 6 at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference in Phoenix, AZ.
  • Part 1 of the clinical trial should be completed by the end of this year.
  • Merakris will discuss its interim data at a workshop on the first day of the four-day Desert Foot Conference.
  • Broderick said the company, which has filed 10 patent applications covering Dermacyte Liquid and its unique mode of action, plans to conduct more clinical studies in the future.

Western Uranium & Vanadium Corp. Announces Brokered LIFE Financing Up to 7.25 Million

Retrieved on: 
Monday, December 4, 2023

Toronto, Ontario and Nucla, Colorado, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Western Uranium & Vanadium Corp. (CSE: WUC) (OTCQX: WSTRF) (“Western” or the ”Company”) is pleased to announce that it has entered into an agency agreement with A.G.P.

Key Points: 
  • Toronto, Ontario and Nucla, Colorado, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Western Uranium & Vanadium Corp. (CSE: WUC) (OTCQX: WSTRF) (“Western” or the ”Company”) is pleased to announce that it has entered into an agency agreement with A.G.P.
  • The securities issuable pursuant to the LIFE exemption will not be subject to any statutory hold period under applicable Canadian securities laws.
  • The commission will be comprised of a cash commission equal to 7% of the gross proceeds so raised in the Offering.
  • This press release does not constitute an offer to sell or a solicitation to buy anysecurities in any jurisdiction.

Investors Say Acelyrin (SLRN) Lied About Drug Candidate’s Progress - Hagens Berman

Retrieved on: 
Monday, December 4, 2023

SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now .
  • Investors learned the truth on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate to severe HS.
  • This news drove the price of Acelyrin shares plummeting $17.19 lower during the two trading days ended Sept. 13, 2023.
  • “We’re focused on investors’ losses and are investigating whether Acelyrin may have concealed data that did not support the hypothesized benefits of izokibep,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

ACELYRIN SHAREHOLDER ALERT: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options

Retrieved on: 
Saturday, December 2, 2023

NEW YORK, Dec. 02, 2023 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acelyrin, Inc. (“Acelyrin” or the “Company”) (NASDAQ: SLRN) and reminds investors of the January 16, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $50,000 investing in Acelyrin securities between May 4, 2023 and September 11, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Acelyrin’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

HAGENS BERMAN Alerts Acelyrin (SLRN) Investors to Pending Securities Fraud Class Action, Encourages Investors Who Suffered Substantial Losses to Contact Firm’s Attorneys

Retrieved on: 
Friday, December 1, 2023

Investors learned the truth on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate to severe HS.

Key Points: 
  • Investors learned the truth on Sept. 11, 2023, when Acelyrin announced disappointing top-line results from Part B of the Phase 2b/3 trial evaluating izokibep for the treatment of moderate to severe HS.
  • The company said izokibep failed to show statistically significant reduction in abscesses and inflammatory nodules in patients as compared to placebo.
  • This news drove the price of Acelyrin shares plummeting $17.19 lower during the two trading days ended Sept. 13, 2023.
  • “We’re focused on investors’ losses and are investigating whether Acelyrin may have concealed data that did not support the hypothesized benefits of izokibep,” said Reed Kathrein, the Hagens Berman partner leading the investigation.